Reagent and kit for diagnosing CML blast phase based on hnrnpa1 splice variant

Abstract

The invention discloses application of No.8 exon skip / retained spliceosome (hnRNPA1-a and hnRNPA1-b) of hnRNPA1 in preparing a reagent for diagnosing chronic myeloid leukemia blast crisis or in a kitcontaining the diagnostic reagent. The reagent has higher sensitivity and specificity, can observe the chronic myeloid leukemia blast crisis more simply, accurately and early so as to timely take treatment means, and has higher clinical application value.

Description

technical field [0001] The present invention relates to the application of hnRNPA1 splicing variant as a marker in diagnosing patients with chronic myelogenous leukemia in blast phase, as well as the application in preparing corresponding detection reagents and kits. Background technique [0002] Chronic myeloid leukemia (CML) is a malignant proliferative disease originating from pluripotent hematopoietic stem cells, accounting for about 20% of human leukemias. Studies have found that about 95% of CML patients have abnormal cytogenetic changes, that is, reciprocal translocation of chromosome 9 and chromosome 22 to form Philadelphia chromosome (philadelphia, Ph) and Bcr-Abl fusion gene. BCR / ABL fusion protein has strong tyrosine kinase activity, abnormally activates multiple downstream signaling pathways, and stimulates abnormal proliferation and malignant transformation of hematopoietic cells. The course of CML is usually divided into three stages: chronic phase, accelerate...

AI Technical Summary

Problems solved by technology

Although some previous research reports have confirmed that alternative splicing plays an important role in the development of CML, there is no report on alternative splicing, including the report that hnRNPA1 alternative splicing may regulate the abnormal splicing of pre-mRNA and participate in the progression of slow-grain blast. There is an urgent need in the field for early, accurate and specific detection of CML blasts

Images